RoukenBio and AVS Bio have formed a strategic partnership aimed at streamlining the development of therapeutic antibodies by combining discovery, optimization and early functional testing into a single, integrated workflow. AVS Bio, which focuses on design‑driven antibody discovery, will contribute its platforms for generating broad candidate diversity—including single‑B‑cell, phage display and hybridoma technologies—as well as its in‑silico optimization tools used to assess developability an...